Patheon set for softgel capsule production at Cincinnati

By Gareth Macdonald

- Last updated on GMT

Related tags Credit

Contract manufacturing organisation (CMO) Patheon has installed new soft gel manufacturing capacity at its facility in Cincinnati in response to “an unmet customer need.”

Spokesperson Wendy Wilson told Outsourcing-pharma that: “Customers have been looking for a top-tier supplier for softgel capsules that has Patheon's performance levels for some time.”

Wilson went on to say that the new manufacturing capacity suits development and small scale commercial projects and “should be operational within the next 30 to 60 days​.”

In a press statement, CEO Wes Wheeler said the expansion compliments the existing liquid filled, hard gelatin capsule lines at the facility and “creates a more comprehensive service offering​.”

The CMO also appointed Edgar Jaynes as its new associate director of pharmaceutical development services at the site, explaining that his “broad industry experience​” includes expertise in soft gel technology.

Expansion in the softgel capsules sector will increase the competition between Patheon and rival CMOs such as New Jersey, US-based Catalent and Pfizer’s Capsugel unit, which both have existing manufacturing capacity.

Raises $280m through private placement

In other news, Patheon recently announced that is will raise around $280m through a private placement of secured notes, equivalent to 8.6 per cent of the company.

The firm said that the move will allow it to repay “outstanding indebtedness under the company’s existing senior secured term loan and asset based revolving credit facility, to repay certain other indebtedness and to pay related fees and expenses​.”

Patheon did not disclose the name of the investor.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us